Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
Background Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers where a primary tissue of origin (TOO) is uncertain. Most patients with CUP have limited treatment options and poor survival outcomes. Immune checkpoint inhibitors (ICIs) can be efficacious in some patients wit...
Main Authors: | Madhu Singh, Linda Mileshkin, Penelope Schofield, Bo Gao, Gary Richardson, Andrew Pattison, Rodney J Hicks, Niko Thio, Mark Warren, Colin Wood, Stephen B Fox, Anna DeFazio, Andrew Fellowes, Christopher Steer, David Bowtell, Nicholas Wilcken, Tharani Sivakumaran, Atara Posner, Dariush Etemadmoghadam, Krista Fisher, Samantha Webb, Christos S Karapetis, Ian M Collins, Narayan Karanth, Owen W J Prall, Richard William Tothill |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/11/1/e005809.full |
Similar Items
-
High resolution melting for mutation scanning of <it>TP53 </it>exons 5–8
by: Fox Stephen B, et al.
Published: (2007-08-01) -
High resolution melting for mutation scanning of TP53exons 5–8
by: Krypuy, M, et al.
Published: (2007) -
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin
by: Anna Ugalde, et al.
Published: (2025-01-01) -
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
by: Ahmed, A, et al.
Published: (2010) -
Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis.
by: Catherine Emmanuel, et al.
Published: (2011-01-01)